(Q38774498)

6 September 2017

title

Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer (English)

1 reference

6 September 2017

1 reference

1 reference

HyeRan Gwak

1

1 reference

6 September 2017

Youngmin Kim

2

1 reference

6 September 2017

Haein An

3

1 reference

6 September 2017

Danny N Dhanasekaran

4

1 reference

6 September 2017

Yong Sang Song

5

1 reference

6 September 2017

publication date

29 April 2016

1 reference

6 September 2017

published in

Molecular Carcinogenesis

1 reference

6 September 2017

volume

56

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

349-358

1 reference

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

6 September 2017

cites work

1 reference

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects

21 January 2018

1 reference

Glucose as a prognostic factor in ovarian carcinoma

21 January 2018

1 reference

Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary

21 January 2018

1 reference

Metformin intake is associated with better survival in ovarian cancer: a case-control study

21 January 2018

1 reference

Metformin targets ovarian cancer stem cells in vitro and in vivo

21 January 2018

1 reference

Metformin--mode of action and clinical implications for diabetes and cancer

21 January 2018

1 reference

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer

21 January 2018

1 reference

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer

21 January 2018

1 reference

Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells

21 January 2018

1 reference

Autophagy and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α) pathway protect ovarian cancer cells from metformin-induced apoptosis

21 January 2018

1 reference

Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells

21 January 2018

1 reference

GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy

21 January 2018

1 reference

A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).

21 January 2018

1 reference

21 January 2018

The renaissance of GSK3

1 reference

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

21 January 2018

1 reference

Metabolic approaches to overcoming chemoresistance in ovarian cancer.

21 January 2018

1 reference

Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.

21 January 2018

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression

21 January 2018

1 reference

Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells

21 January 2018

1 reference

Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy

21 January 2018

1 reference

Cyclin D as a therapeutic target in cancer

21 January 2018

1 reference

Signal integration by JNK and p38 MAPK pathways in cancer development

21 January 2018

1 reference

The LKB1-AMPK pathway-friend or foe in cancer?

21 January 2018

1 reference

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

21 January 2018

1 reference

Activator or inhibitor? GSK-3 as a new drug target

21 January 2018

1 reference

GSK-3beta as a driving force in ovarian cancer

21 January 2018

1 reference

Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance

21 January 2018

1 reference

Beyond chemotherapy: targeted therapies in ovarian cancer

21 January 2018

1 reference

Epidemiological characteristics of ovarian cancer in Korea

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MC.22498

1 reference

6 September 2017

1 reference